Syneron (ELOS) to Aquire Ultrashape in $12M Cash Deal
Tweet
Share
E-mailGet Alerts ELOS Hot Sheet
Join SI Premium – FREE
Syneron Medical Ltd. (Nasdaq: ELOS), has signed a definitive agreement to acquire Ultrashape Ltd., a developer, manufacturer and marketer of innovative non-invasive technologies for fat cell destruction and body sculpting.
Ultrashape is the sole operating entity of Ultrashape Medical and it owns all rights and interests in the fat cell reduction and body sculpting business. Ultrashape's products are approved and commercially available in Europe, Canada, Latin America and Asia.
Under terms of the agreement, Syneron will acquire 100% of the outstanding shares of Ultrashape Ltd. from Ultrashape Medical Ltd. for $12.0 million in cash. The acquisition is subject to customary closing conditions and is expected to close by the end of Q112.
Ultrashape is the sole operating entity of Ultrashape Medical and it owns all rights and interests in the fat cell reduction and body sculpting business. Ultrashape's products are approved and commercially available in Europe, Canada, Latin America and Asia.
Under terms of the agreement, Syneron will acquire 100% of the outstanding shares of Ultrashape Ltd. from Ultrashape Medical Ltd. for $12.0 million in cash. The acquisition is subject to customary closing conditions and is expected to close by the end of Q112.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bernstein on whether Hershey (HSY) could eventually step up to buy Mondelez (MDLZ)
- UraniumX acquires Dieter Lake uranium project in all-share deal
- Treasure Global sells shares in two deals worth $6.6M total
Create E-mail Alert Related Categories
Mergers and AcquisitionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
